XRAY
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but lacks the earnings to justify a traditional value play.
- Low P/S (0.65)
- Low Forward P/E (7.67)
- Negative current P/E
- Lack of Graham Number baseline
Revenue growth is insufficient to offset the collapse in bottom-line profitability.
- Steady 6% revenue growth
- Extreme EPS decline
- Poor earnings surprise track record
Consistent long-term destruction of shareholder value.
- -80% 5-year change
- -68.7% 3-year change
The Piotroski score confirms the company is in a weak financial state.
- Current Ratio > 1.0
- Piotroski F-Score 2/9
- Negative ROE
- Debt/Equity of 1.85
Yield is high, but the lack of profit makes the dividend high-risk.
- 5.04% Yield
- Low Payout Ratio (28.83%)
- Paid from a position of negative net income
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for XRAY and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
XRAY
DENTSPLY SIRONA Inc.
Primary
|
-80.0% | -68.7% | -7.0% | -8.3% | +3.8% | -1.6% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
NKTR
Nektar Therapeutics
Peer
|
-72.0% | +482.5% | +802.9% | +42.4% | +12.5% | +6.6% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
RARE
Ultragenyx Pharmaceutical Inc.
Peer
|
-76.5% | -39.5% | -30.5% | -24.0% | +21.3% | +6.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
XRAY
DENTSPLY SIRONA Inc.
|
BEARISH | $2.38B | - | -36.4% | -16.2% | $11.9 | |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
NKTR
Nektar Therapeutics
|
BEARISH | $2.33B | - | -217.9% | -297.1% | $81.26 | Compare |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
|
RARE
Ultragenyx Pharmaceutical Inc.
|
BEARISH | $2.44B | - | -608.5% | -85.4% | $24.81 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | LUCIER GREGORY T | Director | Purchase | 15,000 | $186,675 |
| 2026-03-09 | FORBES JAMES D | Director | Purchase | 5,000 | $62,400 |
| 2026-03-04 | JOHNSON ROBERT ANTHONY | Officer | Stock Award | 44,643 | - |
| 2026-03-04 | CZERNEY KEVIN J. | Officer | Stock Award | 13,690 | - |
| 2026-03-04 | DENTI ALDO MARIANO ROBERTO | Officer | Stock Award | 59,524 | - |
| 2026-03-04 | FROHNING ANDREA L | Officer | Stock Award | 26,786 | - |
| 2026-03-04 | SCAVILLA DANIEL T | Chief Executive Officer | Stock Award | 145,089 | - |
| 2026-03-03 | LUCIER GREGORY T | Director | Purchase | 50,000 | $707,379 |
| 2026-03-03 | FORBES JAMES D | Director | Purchase | 5,000 | $67,345 |
| 2026-03-02 | JOHNSON ROBERT ANTHONY | Officer | Stock Award | 9,599 | - |
| 2026-03-02 | CZERNEY KEVIN J. | Officer | Stock Award | 1,478 | - |
| 2026-03-02 | FROHNING ANDREA L | Officer | Stock Award | 8,861 | - |
| 2026-01-26 | ZURBAY DONALD J | Director | Stock Award | 6,871 | - |
| 2026-01-09 | BARBER MICHAEL J | Director | Stock Award | 245 | - |
| 2026-01-09 | LUCIER GREGORY T | Director | Stock Award | 341 | - |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
XRAY has filed its 10-K for the period ending February 2026, which includes standard disclosures regarding financial condition, market risk, and risk factors. The provided excerpts contain only the filing's structural index and forward-looking statement disclaimers, omitting specific financial metrics and detailed risk descriptions.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning XRAY from our newsroom.